Cargando…

Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey

OBJECTIVES: To determine the feasibility of collecting population-based patient-reported outcome measures (PROMs) in assessing quality of life (QoL) to inform the development of a national PROMs programme for cancer and to begin to describe outcomes in a UK cohort of survivors. DESIGN: Cross-section...

Descripción completa

Detalles Bibliográficos
Autores principales: Glaser, Adam W, Fraser, Lorna K, Corner, Jessica, Feltbower, Richard, Morris, Eva J A, Hartwell, Greg, Richards, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641492/
https://www.ncbi.nlm.nih.gov/pubmed/23578682
http://dx.doi.org/10.1136/bmjopen-2012-002317
_version_ 1782268034824536064
author Glaser, Adam W
Fraser, Lorna K
Corner, Jessica
Feltbower, Richard
Morris, Eva J A
Hartwell, Greg
Richards, Mike
author_facet Glaser, Adam W
Fraser, Lorna K
Corner, Jessica
Feltbower, Richard
Morris, Eva J A
Hartwell, Greg
Richards, Mike
author_sort Glaser, Adam W
collection PubMed
description OBJECTIVES: To determine the feasibility of collecting population-based patient-reported outcome measures (PROMs) in assessing quality of life (QoL) to inform the development of a national PROMs programme for cancer and to begin to describe outcomes in a UK cohort of survivors. DESIGN: Cross-sectional postal survey of cancer survivors using a population-based sampling approach. SETTING: English National Health Service. PARTICIPANTS: 4992 breast, colorectal, prostate and non-Hodgkin's lymphoma (NHL) survivors 1–5 years from diagnosis. PRIMARY AND SECONDARY OUTCOME MEASURES: Implementation issues, response rates, cancer-specific morbidities utilising items including the EQ5D, tumour-specific subscales of the Functional Assessment of Cancer Therapy and Social Difficulties Inventory. RESULTS: 3300 (66%) survivors returned completed questionnaires. The majority aged 85+ years did not respond and the response rates were lower for those from more deprived area. Response rates did not differ by gender, time since diagnosis or cancer type. The presence of one or more long-term conditions was associated with significantly lower QoL scores. Individuals from most deprived areas reported lower QoL scores and poorer outcomes on other measures, as did those self-reporting recurrent disease or uncertainty about disease status. QoL scores were comparable at all time points for all cancers except NHL. QoL scores were lower than those from the general population in Health Survey for England (2008) and General Practice Patient Survey (2012). 47% of patients reported fear of recurrence, while 20% reported moderate or severe difficulties with mobility or usual activities. Bowel and urinary problems were common among colorectal and prostate patients. Poor bowel and bladder control were significantly associated with lower QoL. CONCLUSIONS: This method of assessing QoL of cancer survivors is feasible and acceptable to most survivors. Routine collection of national population-based PROMs will enable the identification of, and the support for, the specific needs of survivors while allowing for comparison of outcome by service provider.
format Online
Article
Text
id pubmed-3641492
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36414922013-05-07 Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey Glaser, Adam W Fraser, Lorna K Corner, Jessica Feltbower, Richard Morris, Eva J A Hartwell, Greg Richards, Mike BMJ Open Oncology OBJECTIVES: To determine the feasibility of collecting population-based patient-reported outcome measures (PROMs) in assessing quality of life (QoL) to inform the development of a national PROMs programme for cancer and to begin to describe outcomes in a UK cohort of survivors. DESIGN: Cross-sectional postal survey of cancer survivors using a population-based sampling approach. SETTING: English National Health Service. PARTICIPANTS: 4992 breast, colorectal, prostate and non-Hodgkin's lymphoma (NHL) survivors 1–5 years from diagnosis. PRIMARY AND SECONDARY OUTCOME MEASURES: Implementation issues, response rates, cancer-specific morbidities utilising items including the EQ5D, tumour-specific subscales of the Functional Assessment of Cancer Therapy and Social Difficulties Inventory. RESULTS: 3300 (66%) survivors returned completed questionnaires. The majority aged 85+ years did not respond and the response rates were lower for those from more deprived area. Response rates did not differ by gender, time since diagnosis or cancer type. The presence of one or more long-term conditions was associated with significantly lower QoL scores. Individuals from most deprived areas reported lower QoL scores and poorer outcomes on other measures, as did those self-reporting recurrent disease or uncertainty about disease status. QoL scores were comparable at all time points for all cancers except NHL. QoL scores were lower than those from the general population in Health Survey for England (2008) and General Practice Patient Survey (2012). 47% of patients reported fear of recurrence, while 20% reported moderate or severe difficulties with mobility or usual activities. Bowel and urinary problems were common among colorectal and prostate patients. Poor bowel and bladder control were significantly associated with lower QoL. CONCLUSIONS: This method of assessing QoL of cancer survivors is feasible and acceptable to most survivors. Routine collection of national population-based PROMs will enable the identification of, and the support for, the specific needs of survivors while allowing for comparison of outcome by service provider. BMJ Publishing Group 2013-04-12 /pmc/articles/PMC3641492/ /pubmed/23578682 http://dx.doi.org/10.1136/bmjopen-2012-002317 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode
spellingShingle Oncology
Glaser, Adam W
Fraser, Lorna K
Corner, Jessica
Feltbower, Richard
Morris, Eva J A
Hartwell, Greg
Richards, Mike
Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey
title Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey
title_full Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey
title_fullStr Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey
title_full_unstemmed Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey
title_short Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey
title_sort patient-reported outcomes of cancer survivors in england 1–5 years after diagnosis: a cross-sectional survey
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641492/
https://www.ncbi.nlm.nih.gov/pubmed/23578682
http://dx.doi.org/10.1136/bmjopen-2012-002317
work_keys_str_mv AT glaseradamw patientreportedoutcomesofcancersurvivorsinengland15yearsafterdiagnosisacrosssectionalsurvey
AT fraserlornak patientreportedoutcomesofcancersurvivorsinengland15yearsafterdiagnosisacrosssectionalsurvey
AT cornerjessica patientreportedoutcomesofcancersurvivorsinengland15yearsafterdiagnosisacrosssectionalsurvey
AT feltbowerrichard patientreportedoutcomesofcancersurvivorsinengland15yearsafterdiagnosisacrosssectionalsurvey
AT morrisevaja patientreportedoutcomesofcancersurvivorsinengland15yearsafterdiagnosisacrosssectionalsurvey
AT hartwellgreg patientreportedoutcomesofcancersurvivorsinengland15yearsafterdiagnosisacrosssectionalsurvey
AT richardsmike patientreportedoutcomesofcancersurvivorsinengland15yearsafterdiagnosisacrosssectionalsurvey